Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, retaining the price target of $89.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Edward Nash’s rating is based on the promising results from Apogee Therapeutics’ Phase II APEX study for their IL-13 monoclonal antibody, APG777, targeting atopic dermatitis. The study successfully met its primary and secondary endpoints, showing a significant reduction in the Eczema Area and Severity Index Score (EASI) and other efficacy measures. This positive outcome suggests a robust effect of the drug, with a notable reduction in EASI scores observed as early as Week 2.
Furthermore, the ongoing Part B of the APEX study and the anticipated 52-week maintenance data, expected in the first half of 2026, add to the confidence in the drug’s potential. The data indicates a high likelihood of success for effective quarterly to semi-annual dosing, supported by the well-established mechanism of action in atopic dermatitis treatment. These factors contribute to Nash’s Buy rating and the $89 12-month price target for Apogee Therapeutics’ stock.
According to TipRanks, Nash is a 5-star analyst with an average return of 14.9% and a 46.80% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Celldex, and Apogee Therapeutics.
In another report released today, Citi also maintained a Buy rating on the stock with a $95.00 price target.